AEON Biopharma, Inc., based in Newport Beach, California, is at the forefront of the biopharmaceutical sector, specializing in the development of advanced botulinum toxin products aimed at addressing a range of debilitating medical conditions. The company stands out with its emphasis on proprietary formulations, strategically positioning itself within the growing neuromodulators market. AEON's innovative pipeline and commitment to enhancing treatment outcomes not only underscore its potential for significant market impact but also highlight its role as a key player in shaping the future of therapeutic and aesthetic interventions. As the demand for effective solutions continues to rise, AEON is well-equipped to capitalize on emerging opportunities in the evolving healthcare landscape.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

5 PARK PLAZA, IRVINE, CA, UNITED STATES, 92614

December

$10.9 Million

-$17.9 Million

0.0

-13.91

$0.00

0.0%

0.753